BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9879342)

  • 1. The causes and prognostic significance of low hemoglobin levels in tumor patients.
    Manegold C
    Strahlenther Onkol; 1998 Dec; 174 Suppl 4():17-9. PubMed ID: 9879342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors.
    Steinmetz T; Hellmich M; Neise M; Aldaud A; Lerchenmüller C; Tsamaloukas A; Fandel F; Weiligmann C; Totzke U; Schmitz S
    Oncologist; 2007 Jun; 12(6):748-55. PubMed ID: 17602064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial experience using erythropoietin during radiation therapy.
    Lavey RS
    Strahlenther Onkol; 1998 Dec; 174 Suppl 4():24-30. PubMed ID: 9879344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
    Desai J; Demetri GD
    Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
    Wang W; Zhang MH; Yu Y; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].
    Lastiri JM; Specterman SR; Rendo P; Pallotta MG; Varela MS; Goldstein S
    Medicina (B Aires); 2002; 62(1):41-7. PubMed ID: 11965849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of erythropoietin in anemia after heart transplantation.
    Gleissner CA; Klingenberg R; Staritz P; Koch A; Ehlermann P; Wiggenhauser A; Dengler TJ
    Int J Cardiol; 2006 Oct; 112(3):341-7. PubMed ID: 16309765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma.
    Tanvetyanon T; Choudhury AM
    Cancer; 2006 Apr; 106(7):1554-9. PubMed ID: 16518817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rHuEPO and treatment outcomes: the clinical experience.
    Hudis CA; Van Belle S; Chang J; Muenstedt K
    Oncologist; 2004; 9 Suppl 5():55-69. PubMed ID: 15591423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anemia impact on treatments of cervical carcinomas].
    Marchal C; Rangeard L; Brunaud C
    Cancer Radiother; 2005 Mar; 9(2):87-95. PubMed ID: 15820436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B; van de Werf PR; Melissant CF; Brok RG
    Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors].
    Oudard S; Quoix E; Jenabian A; Bergougnoux L; Chouahnia K; Ferrero JM; Misset JL; Spaëth D
    Therapie; 2009; 64(1):17-25. PubMed ID: 19463249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.
    Fishbane S
    Blood Purif; 2007; 25(1):53-7. PubMed ID: 17170538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia of chronic disease: a review of pathogenesis.
    DeRienzo DP; Saleem A
    Tex Med; 1990 Oct; 86(10):80-3. PubMed ID: 2247849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.